Deal Watch: Gilead Continues To Add To IO Armamentarium In Collaboration With Gadeta

20 Jul 2018

• By Joseph Haas, Ian Haydock, and John Davis

Deal through Kite Pharma subsidiary focuses on developing gamma delta T-cell receptor therapies. Sanofi inks SHP2 cancer collaboration with Revolution, while Vical considers its strategic options.

Deal Watch: Gilead Continues To Add To IO Armamentarium In Collaboration With Gadeta

More from Deals

More from Business